Screener
Artiva Biotherapeutics, Inc. ARTV Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| Line item | SIX MONTHS ENDED JUNE 30, 2026 | SIX MONTHS ENDED JUNE 30, 2025 |
|---|---|---|
| Payments to taxing authorities related to net-settlement of vested restricted stock units | (210) | (39) |
| Payments on finance leases | (45) | (66) |
| Net cash provided by financing activities | 283,157 | 167 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 274,753 | (11,564) |
| Cash, cash equivalents and restricted cash at beginning of period | 27,162 | 40,493 |
| Cash, cash equivalents and restricted cash at end of period | $301,915 | $28,929 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: | ||
| Cash and cash equivalents | $301,454 | $28,468 |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s net change in cash?
- Artiva Biotherapeutics, Inc. (ARTV) reported net change in cash of $280.5M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s net change in cash changed year-over-year?
- Artiva Biotherapeutics, Inc.'s net change in cash increased by 14611.1% year-over-year, from -$1.93M to $280.5M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Artiva Biotherapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude